Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Revance Therapeutics, Inc. (RVNC)

21.37   -0.36 (-1.66%) 12-07 16:00
Open: 21.96 Pre. Close: 21.73
High: 22.23 Low: 21.225
Volume: 766,057 Market Cap: 1,758(M)

Technical analysis

as of: 2022-12-07 4:25:43 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 26.14     One year: 28.61
Support: Support1: 18.95    Support2: 15.77
Resistance: Resistance1: 22.38    Resistance2: 24.5
Pivot: 22.16
Moving Average: MA(5): 21.62     MA(20): 22.26
MA(100): 22.52     MA(250): 18.21
MACD: MACD(12,26): -0.5     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 19.3     %D(3): 21
RSI: RSI(14): 42.6
52-week: High: 30.95  Low: 11.27
Average Vol(K): 3-Month: 1,362 (K)  10-Days: 899 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ RVNC ] has closed above bottom band by 16.1%. Bollinger Bands are 61.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 22.26 - 22.37 22.37 - 22.47
Low: 20.97 - 21.09 21.09 - 21.18
Close: 21.2 - 21.38 21.38 - 21.53

Company Description

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Headline News

Mon, 28 Nov 2022
Should You Buy Revance Therapeutics Inc (RVNC) Stock on Monday? - InvestorsObserver

Thu, 17 Nov 2022
Nanostics Announces New Member of Board of Directors - PR Newswire

Thu, 10 Nov 2022
Recent 8.2% pullback isn't enough to hurt long-term Revance Therapeutics (NASDAQ:RVNC) shareholders, they're still up 39% over 1 year - Simply Wall St

Tue, 08 Nov 2022
Revance Therapeutics, Inc. (RVNC) Q3 2022 Earnings Call Transcript - Seeking Alpha

Tue, 01 Nov 2022
Here’s What Makes Revance Therapeutics (RVNC) an Attractive Investment - Yahoo Finance

Mon, 24 Oct 2022
Revance Therapeutics, Inc. (NASDAQ:RVNC) insiders are undoubtedly delighted they bought last year with gains to date at US$736k - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 82 (M)
Shares Float 75 (M)
% Held by Insiders 2.4 (%)
% Held by Institutions 89.7 (%)
Shares Short 9,560 (K)
Shares Short P.Month 9,370 (K)

Stock Financials

EPS -4.04
EPS Est Next Qtl -0.94
EPS Est This Year -3.61
EPS Est Next Year -3.42
Book Value (p.s.) 1.76
Profit Margin (%) -252
Operating Margin (%) -238.7
Return on Assets (ttm) -25.1
Return on Equity (ttm) -205.8
Qtrly Rev. Growth 46.9
Gross Profit (p.s.) -0.76
Sales Per Share 1.31
EBITDA (p.s.) -2.84
Qtrly Earnings Growth 0
Operating Cash Flow -208 (M)
Levered Free Cash Flow -113 (M)

Stock Valuations

PE Ratio -5.29
PEG Ratio -0.5
Price to Book value 12.07
Price to Sales 16.19
Price to Cash Flow -8.46

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.